Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:04 AM ET 8-K
Regulatory Approval Mirum Pharmaceuticals, Inc. MIRM

Mirum Pharmaceuticals Regulatory Approval

The FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older. The drug, licensed from Incyte, is a first-of-its-kind oral ALK2 inhibitor designed to reduce new heterotopic ossification (abnormal bone formation). Mirum expects the product to be commercially available in the U.S. in October 2026.

Counterparty
Incyte Corporation
8:02 AM ET 8-K
Licensing Deal Ainos, Inc. AIMD

Ainos Licensing Deal with BioPhoenix Co., Ltd. Worth $10M

Ainos entered into a global exclusive license agreement with BioPhoenix for its VELDONA low-dose oral interferon alpha technology platform for Sjögren’s Disease and Thrombocytopenia. Ainos will receive an upfront fee of $600,000 and is eligible for up to $10.0 million in total fees if additional indications are licensed, plus 25% of net sublicensing revenue. BioPhoenix will assume all clinical and regulatory funding and execution for the licensed indications.

Value
$10M
Counterparty
BioPhoenix Co., Ltd.
Term
20 years
8:02 AM ET 8-K
Clinical Trial Data Keros Therapeutics, Inc. KROS

Keros Therapeutics Clinical Trial Data

Keros Therapeutics announced the dosing of the first patient in its Phase 2 clinical trial evaluating rinvatercept for the treatment of Duchenne muscular dystrophy (DMD). The open-label, multi-cohort trial will assess safety, tolerability, and functional improvements in ambulatory and non-ambulatory patients, with initial data expected in the first half of 2027.

8:02 AM ET 8-K
Capital Raise Strategy Inc MSTR

Strategy Capital Raise of $246M

Strategy Inc raised $246.2 million in net proceeds through the sale of 1,469,165 shares of Class A Common Stock under its at-the-market (ATM) offering program between September 21 and September 27, 2026. The company utilized $142.7 million of the proceeds to purchase 1,665 additional bitcoins and $103.5 million to fund repurchases of its STRC preferred stock. As of September 27, 2026, the company held a total of 847,666 bitcoins acquired at an aggregate purchase price of approximately $63.95 billion.

Value
$246M
8:02 AM ET 8-K
M&A Deal Lakeshore Acquisition III Corp. LCCC

Lakeshore Acquisition III M&A Deal with CPRO Electronics Co. Ltd.

Lakeshore Acquisition III Corp. has extended the deadline to complete its initial business combination from October 1, 2026, to November 1, 2026. The extension was triggered by a $67,500 payment into the company's trust account by its merger partner, CPRO Electronics Co. Ltd., pursuant to their existing merger agreement.

Counterparty
CPRO Electronics Co. Ltd.
Term
1 month
7:43 AM ET 8-K
M&A Deal TransDigm Group INC TDG

TransDigm Group Signs $1.07B M&A Deal with Prince & Izant

TransDigm Group completed the acquisition of Prince & Izant, a manufacturer of highly engineered brazing alloys and specialty metal components, for approximately $1.066 billion in cash. The acquisition, financed with cash on hand, expands TransDigm's presence in the aerospace and defense aftermarket and is expected to generate $390 million in revenue for calendar year 2026.

Value
$1.07B
Counterparty
Prince & Izant
7:38 AM ET 8-K
M&A Deal Valley National Bancorp VLY

Valley National Bancorp Signs $340M M&A Deal with Bluevine Inc.

Valley National Bancorp (VLY) has entered into a definitive agreement to acquire Bluevine Inc., a digital banking platform for small businesses, for approximately $340 million. The deal consists of $255 million in cash and approximately 6.3 million shares of Valley common stock, aimed at enhancing Valley's core funding base and accelerating its digital and AI strategy. Bluevine brings approximately $2.1 billion in low-cost deposits and 175,000 active small business customers to the combined organization.

Value
$340M
Counterparty
Bluevine Inc.
Earnings call
Sep 28, 2026, 8:30 AM ET
7:32 AM ET 8-K
Partnership Soluna Holdings, Inc SLNH

Soluna Holdings Partnership with Bitdeer Technologies Group

Soluna Holdings expanded its co-mining partnership with Bitdeer Technologies Group to deploy an additional 7 MW of Bitcoin mining equipment at its Project Kati 1 site in Texas. This amendment brings Bitdeer's total deployment at the site to 35 MW (approximately 2.42 EH/s), fully subscribing the site's K1BC phase under a revenue-sharing structure.

Counterparty
Bitdeer Technologies Group
7:16 AM ET 8-K
Product Launch Eton Pharmaceuticals, Inc. ETON

Eton Pharmaceuticals Product Launch

Eton Pharmaceuticals has launched IMPAVIDO (miltefosine) capsules in the United States for the treatment of visceral, cutaneous, and mucosal leishmaniasis. The company has integrated the product into its Eton Cares rare disease commercial infrastructure, providing patient support services and centralized distribution through Anovo Specialty Pharmacy.

7:03 AM ET 8-K
Clinical Trial Data Moleculin Biotech, Inc. MBRX

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced the peer-reviewed publication of a pooled cardiac safety analysis of its drug candidate Annamycin in Frontiers in Cardiovascular Medicine. The analysis of 90 patients across five clinical trials found no clinical or subclinical evidence of cardiotoxicity, even at cumulative doses exceeding traditional anthracycline limits.

Counterparty
Cleveland Clinic

“Publication of this comprehensive pooled analysis in a peer-reviewed cardiovascular medicine journal provides additional validation of the cardiac safety profile we have observed with Annamycin across our clinical development program. For decades, the clinical utility of anthracyclines has been limited by cumulative cardiotoxicity and associated lifetime dose limits. The absence of detectable cardiac toxicity in patients receiving cumulative doses of Annamycin beyond those traditional thresholds supports our continued development of Annamycin and its potential to address an important limitation of the anthracycline class.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin
6:47 AM ET 8-K
M&A Deal Ftai Infrastructure Inc. FIP

Ftai Infrastructure Signs $255M M&A Deal with DRUbit Holdings LLC

FTAI Infrastructure's subsidiary entered into a definitive agreement to acquire the Port Arthur Terminal and a 50% interest in a Diluent Recovery Unit from USD Group LLC for $255 million. The acquisition includes an integrated origin-to-destination logistics platform for crude oil shipment under a long-term, take-or-pay contract with an investment-grade counterparty. The deal is expected to generate approximately $50 million of annual EBITDA and close in the fourth quarter of 2026.

Value
$255M
Counterparty
DRUbit Holdings LLC (USD Group LLC)
Term
long-term
6:05 AM ET 8-K
M&A Deal Inflection Point Acquisition Corp. V IPEX

Inflection Point Acquisition Corp. V Signs $50M M&A Deal with GOWell Technology Limited

Inflection Point Acquisition Corp. V (SPAC) has completed its business combination with GOWell Technology Limited, a global provider of well logging solutions. The combined entity, renamed GOWell Energy Technology, will trade on Nasdaq under the ticker 'GOW' starting September 28, 2026. The transaction was supported by a $50 million PIPE investment at closing, bringing total private placement proceeds to $70 million.

Value
$50M
Counterparty
GOWell Technology Limited
6:05 AM ET 8-K
Contract Win Amprius Technologies, Inc. AMPX

Amprius Technologies Wins $75M Contract from United States of America

Amprius Technologies was awarded a $75 million fixed-price contract by the U.S. Government for 'Project acCELLerate' to establish domestic high-volume manufacturing of silicon-anode lithium-ion battery cells for small Unmanned Aerial Systems. The U.S. Government has initially obligated $22 million to fund the base period through September 2028, with the company required to meet specific deliverables for milestone payments.

Value
$75M
Counterparty
United States of America (U.S. Government)
Term
through September 22, 2028
6:02 AM ET 8-K
M&A Deal Crown Reserve Acquisition Corp. I CRAC

Crown Reserve Acquisition Corp. I M&A Deal with Carvix, Inc.

Crown Reserve Acquisition Corp. I entered into a second amendment to its business combination agreement with Carvix, Inc. to extend the 'Outside Date' for closing the merger. The deadline for the transaction has been moved from September 30, 2026, to February 10, 2027, or a later date as required by the company's organizational documents.

Counterparty
Carvix, Inc.
5:31 PM ET 8-K
M&A Deal United States 12 Month Natural Gas Fund, LP UNL

United States 12 Month Natural Gas Fund M&A Deal with Madison Dearborn Partners

The Marygold Companies, Inc. (TMC), the ultimate parent company of the fund's general partner, has entered into a definitive agreement to be acquired by private equity firm Madison Dearborn Partners. Upon completion of the all-cash transaction, TMC will become a privately held company and its common stock will be delisted from the NYSE. The deal is expected to close in the first half of 2027, subject to shareholder and regulatory approvals.

Counterparty
Madison Dearborn Partners
5:30 PM ET 8-K
M&A Deal United States Commodity Index Funds Trust USCI

United States Commodity Index Funds Trust M&A Deal with Madison Dearborn Partners

The Marygold Companies, Inc. (TMC), the ultimate parent company of the sponsor for United States Commodity Index Funds Trust, has entered into a definitive agreement to be acquired by private equity firm Madison Dearborn Partners. Upon completion of the all-cash transaction, TMC will become a privately held company and its common stock will be delisted from the NYSE. The deal is expected to close in the first half of 2027, subject to customary closing conditions and regulatory approvals.

Counterparty
Madison Dearborn Partners
5:29 PM ET 8-K
M&A Deal United States Natural Gas Fund, LP UNG

United States Natural Gas Fund M&A Deal with Madison Dearborn Partners

The Marygold Companies, Inc. (TMC), the ultimate parent company of the general partner of United States Natural Gas Fund, LP (UNG), has entered into a definitive agreement to be acquired by private equity firm Madison Dearborn Partners. Upon completion of the all-cash transaction, TMC will become a privately held company and refocus the business of its subsidiary, USCF. The deal is expected to close in the first half of 2027, subject to stockholder and regulatory approvals.

Counterparty
Madison Dearborn Partners
5:29 PM ET 8-K
Nasdaq/NYSE Compliance Notice Southland Holdings, Inc. SLND

Southland Holdings Nasdaq/NYSE Compliance Notice

Southland Holdings received a deficiency notice from NYSE American for failing to meet stockholders' equity requirements, reporting a deficit of $248.2 million as of June 30, 2026. The company has until October 23, 2026, to submit a compliance plan and until March 23, 2028, to regain compliance with the exchange's listing standards. The company's common stock and warrants will continue to trade on the NYSE American during the plan period.

Counterparty
NYSE American LLC
Term
through March 23, 2028
5:29 PM ET 8-K
M&A Deal United States 12 Month Oil Fund, LP USL

United States 12 Month Oil Fund M&A Deal with Madison Dearborn Partners

The Marygold Companies, Inc. (TMC), the ultimate parent company of the general partner of United States 12 Month Oil Fund, LP, has entered into a definitive agreement to be acquired by private equity firm Madison Dearborn Partners. The all-cash transaction will result in TMC becoming a privately held company and is expected to close in the first half of 2027. Following the close, the new owners intend to execute a transformation strategy to refocus the business of the fund's general partner, USCF.

Counterparty
Madison Dearborn Partners
5:29 PM ET 8-K
M&A Deal United States Gasoline Fund, LP UGA

United States Gasoline Fund M&A Deal with Madison Dearborn Partners

The Marygold Companies, Inc. (TMC), the ultimate parent company of United States Gasoline Fund, LP's general partner, has entered into a definitive agreement to be acquired by private equity firm Madison Dearborn Partners. Upon completion of the all-cash transaction, TMC will become a privately held company and intends to refocus the business of its subsidiary, USCF. The deal is expected to close in the first half of 2027, subject to stockholder and regulatory approvals.

Counterparty
Madison Dearborn Partners
5:29 PM ET 8-K
M&A Deal United States Oil Fund, LP USO

United States Oil Fund M&A Deal with Madison Dearborn Partners

The Marygold Companies, Inc. (TMC), the ultimate parent company of United States Oil Fund, LP's general partner, has entered into a definitive agreement to be acquired by private equity firm Madison Dearborn Partners. Upon completion of the all-cash transaction, TMC will become a privately held company and its common stock will be delisted from the NYSE. The deal is expected to close in the first half of 2027, subject to customary closing conditions and regulatory approvals.

Counterparty
Madison Dearborn Partners
5:28 PM ET 8-K
M&A Deal United States Brent Oil Fund, LP BNO

United States Brent Oil Fund M&A Deal with Madison Dearborn Partners

The Marygold Companies, Inc. (TMC), the ultimate parent company of the fund's general partner, has entered into a definitive agreement to be acquired by private equity firm Madison Dearborn Partners. Upon completion of the all-cash transaction, TMC will become a privately held company and its common stock will be delisted from the NYSE. The deal is expected to close in the first half of 2027, subject to stockholder and regulatory approvals.

Counterparty
Madison Dearborn Partners
5:28 PM ET 8-K
Nasdaq/NYSE Compliance Notice Dyadic International Inc DYAI

Dyadic International Nasdaq/NYSE Compliance Notice

Dyadic International received two deficiency notices from Nasdaq for failing to maintain a minimum bid price of $1.00 per share and a minimum Market Value of Listed Securities (MVLS) of $35 million for 30 consecutive business days. The company has 180 calendar days, until March 24, 2027, to regain compliance with both requirements.

Counterparty
The Nasdaq Stock Market LLC
Term
180 days
5:26 PM ET 8-K
Nasdaq/NYSE Compliance Notice Fusemachines Inc. FUSE

Fusemachines Nasdaq/NYSE Compliance Notice

Fusemachines Inc. received a delisting notice from Nasdaq on September 24, 2026, after failing to regain compliance with the $50 million minimum Market Value of Listed Securities (MVLS) requirement by the September 23 deadline. The company intends to request a hearing before the Nasdaq Hearings Panel to stay the delisting and seek an extension to regain compliance. Trading of the company's common stock (FUSE) and warrants (FUSEW) will continue on Nasdaq pending the outcome of the hearing.

Counterparty
Nasdaq Stock Market LLC
5:26 PM ET 8-K
Nasdaq/NYSE Compliance Notice SilverBox Corp IV SBXDF

SilverBox Corp IV Nasdaq/NYSE Compliance Notice

SilverBox Corp IV received a notice from the NYSE indicating that the exchange has commenced proceedings to delist the company's units, Class A ordinary shares, and warrants. The delisting determination was made because the company's average aggregate global market capitalization fell below the $40 million minimum requirement over a 30-day period. Trading on the NYSE has been suspended, and the securities are expected to begin trading on the over-the-counter (OTC) market on September 28, 2026.

Counterparty
New York Stock Exchange
5:26 PM ET 8-K
Nasdaq/NYSE Compliance Notice Calidi Biotherapeutics, Inc. CLDI

Calidi Biotherapeutics Nasdaq/NYSE Compliance Notice

Calidi Biotherapeutics received a deficiency notice from NYSE American for failing to maintain the minimum stockholders' equity requirement of $4.0 million. The company reported stockholders' equity of $3.1 million as of June 30, 2026, and has until October 21, 2026, to submit a plan to regain compliance by March 21, 2028.

Counterparty
NYSE American LLC
Term
through March 21, 2028
5:08 PM ET 8-K
M&A Deal Skydance Corp SKYD

Paramount Skydance M&A Deal with Warner Bros. Discovery, Inc.

Paramount Skydance Corporation provided a status and timeline update on its pending merger with Warner Bros. Discovery, Inc., including setting a record date of October 5, 2026, for a related distribution of 470 million warrants to Class B stockholders. The company also announced it is voluntarily transferring its stock listing from the Nasdaq Global Select Market to the New York Stock Exchange, effective October 6, 2026.

Counterparty
Warner Bros. Discovery, Inc.
5:01 PM ET 8-K
Nasdaq/NYSE Compliance Notice Future Money Acquisition Corp FMAC

Future Money Acquisition Nasdaq/NYSE Compliance Notice

Future Money Acquisition Corporation received a deficiency notice from Nasdaq on September 22, 2026, for failing to timely file its Form 10-Q for the quarter ended July 31, 2026. The company has 60 days to submit a plan to regain compliance and could be granted an extension until March 22, 2027, to file the delinquent report.

Counterparty
The Nasdaq Stock Market LLC
5:01 PM ET 8-K
Nasdaq/NYSE Compliance Notice Netcapital Inc. NCPL

Netcapital Nasdaq/NYSE Compliance Notice

Netcapital Inc. received a deficiency notice from Nasdaq on September 21, 2026, for failing to timely file its Quarterly Report on Form 10-Q and its Annual Report on Form 10-K. The company has until October 23, 2026, to submit a plan to regain compliance, which if accepted, could grant an extension until February 9, 2027. The notice has no immediate effect on the listing of the company's common stock (NCPL).

Counterparty
The Nasdaq Stock Market LLC
5:01 PM ET 8-K
M&A Deal Creative Medical Technology Holdings, Inc. CELZ

Creative Medical Technology Holdings M&A Deal with BioDefense, Inc.

Creative Medical Technology Holdings acquired 4,000,000 shares of BioDefense, Inc. from Creative Acquisition Corp. for $200,000 in cash and 1,000,000 shares of its own common stock. Following the transaction, the company owns 80% of BioDefense, Inc., making it a majority-owned subsidiary.

Counterparty
BioDefense, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.